Journal: JAAD Case Reports

Article Title: Cutaneous lupus erythematosus flare with vitiligo-like depigmentation following the AstraZeneca COVID vaccine

doi: 10.1016/j.jdcr.2022.10.003

Figure Lengend Snippet: Widespread polycyclic annular lesions on the arms, trunk scalp, and hands in a patient 4 days after receiving the second dose of the Oxford–AstraZeneca COVID-19 vaccine (AZD1222) ( A-D ). Resolution of the acute eruption resulted in extensive vitiligo-like post inflammatory depigmentation ( E-G ).

Article Snippet: In summary, we present a case of CLE following the Oxford–AstraZeneca COVID-19 vaccine (AZD1222) with subsequent vitiligo-like depigmentation.

Techniques:

Journal: JAAD Case Reports

Article Title: Cutaneous lupus erythematosus flare with vitiligo-like depigmentation following the AstraZeneca COVID vaccine

doi: 10.1016/j.jdcr.2022.10.003

Figure Lengend Snippet: A, direct immunofluorescence reveals immunoglobulin G antibodies throughout the epidermis ( red ) with C3 deposition ( green ) in the basement membrane consistent with connective tissue disease. B, postulated mechanism of vaccine-induced cutaneous lupus. COVID-19 vaccines trigger innate sensors which lead to type 1 interferon secretion, which results in the activation of cytokine and chemokine cascades. T-cell activation ensues followed by a lichenoid tissue reaction. TLRs , Toll-like receptors

Article Snippet: In summary, we present a case of CLE following the Oxford–AstraZeneca COVID-19 vaccine (AZD1222) with subsequent vitiligo-like depigmentation.

Techniques: Immunofluorescence, Activation Assay

Journal: JAAD Case Reports

Article Title: Cutaneous lupus erythematosus flare with vitiligo-like depigmentation following the AstraZeneca COVID vaccine

doi: 10.1016/j.jdcr.2022.10.003

Figure Lengend Snippet: Summary of reported cutaneous lupus reactions occurring post-COVID vaccination

Article Snippet: In summary, we present a case of CLE following the Oxford–AstraZeneca COVID-19 vaccine (AZD1222) with subsequent vitiligo-like depigmentation.

Techniques: Transformation Assay

Journal: bioRxiv

Article Title: Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease

doi: 10.1101/2022.03.04.479488

Figure Lengend Snippet: a. Dot plots showing ELISA binding (OD 405 ) reactivity of immune sera from COVID-19 convalescent donors (n = 15), spike mRNA-vaccinated donors (n = 10) and SARS-CoV-2 recovered-vaccinated donors (n = 15) to 25-mer peptides corresponding to spike S2 stem-helix regions of human β-(sarbecoviruses: SARS-CoV-1 or 2; merbecovirus: MERS-CoV; embecoviruses: HCoV-HKU1, HCoV-OC43) and α-(HCoV-NL63 and HCoV-229E) coronaviruses. 12 out of 15 (80%) SARS-CoV-2 recovered-vaccinated donor sera show cross-reactive binding to β-CoV spike stem-helix peptides. b. Correlation between binding of infected-vaccinated sera to SARS-CoV-2 stem-helix peptide and the other β-CoV (MERS-CoV, HCoV-HKU1 and HCoV-OC43) stem-helix peptides. Responses for binding to two stem-helix peptides were compared by nonparametric Spearman correlation two-tailed test with 95% confidence interval and the Spearman correlation coefficient (r) and the p-value are indicated. c. A total of 40 S2 stem-helix mAbs were isolated from 9 SARS-CoV-2 recovered-vaccinated donors (CC9, CC24, CC25, CC67, CC68, CC84, CC92, CC95 and CC99). MAbs were isolated by single B cell sorting using SARS-CoV-2 and MERS-CoV S-proteins as baits. Heatmap showing IGVH germline gene usage (colored: VH1–46 (green), VH3–23 (plum) and other V-genes (grey)), lineage information (unique (sky) and expanded (tangerine) lineages) and V-gene nucleotide somatic hypermutations (SHMs). EC 50 ELISA binding titers of mAbs with β- and α-HCoV spike S2 stem-helix region peptides. MAbs showed binding to β- but not α-HCoV derived stem-helix peptides. IC 50 neutralization of mAbs against pseudoviruses of clade1a (SARS-CoV-2 and Pang17), clade 1b (SARS-CoV-1, WIV1, SHC014) sarbecoviruses and MERS-CoV. Spike S2 stem-helix bnAbs, CC40.8, S2P6 and CV3–25 were used as controls for binding and neutralization assays. d. 32 of 40 stem-helix bnAbs were unique clones that neutralized all ACE2-utilizing sarbecoviruses and 23 out of 32 unique mAb neutralized MERS-CoV, in addition to sarbecoviruses.

Article Snippet: Using SARS-CoV-2 and MERS-CoV S-proteins as baits, we sorted antigen-specific single B cells to isolate 40 stem-helix mAbs from 10 COVID-19 convalescent donors who had been recently vaccinated with the Pfizer/BioNTech BNT162b2 (n = 4: CC9, CC92, CC95 and CC99), Johnson & Johnson Ad26.CoV2.S (n = 1: CC67), or Moderna mRNA-1273 (n = 5: CC24, CC25, CC26, CC67, CC84) vaccines ( , , ) ( , , ).

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Infection, Two Tailed Test, Isolation, FACS, Derivative Assay, Neutralization, Clone Assay

Journal: bioRxiv

Article Title: Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease

doi: 10.1101/2022.03.04.479488

Figure Lengend Snippet: a. Two S2 stem-helix bnAbs (CC68.109 and CC99.103) individually, or a DEN3 control antibody were administered intra-peritoneally (i.p.) at 300μg per animal into 9 groups of aged mice (10 animals per group). Each group of animals was challenged intra-nasally (i.n.) 12h after antibody infusion with one of 3 mouse-adapted (MA) betacoronaviruses, (MA10-SARS-2 = SARS-CoV-2; 1 × 10 3 plaque forming units (PFU), MA15-SARS1 = SARS-CoV-1; 1 × 10 5 PFU or M35c4-MERS = MERS-CoV; 1 × 10 3 PFU). As a control, groups of mice were exposed only to PBS in the absence of virus . b., e., h. Percent weight change in S2 stem-helix bnAbs or DEN3 control antibody-treated animals after challenge with mouse-adapted betacoronaviruses. Percent weight change was calculated from day 0 starting weight for all animals. c., f., i. Day 2 post-infection Hemorrhage (Gross Pathology score) scored at tissue harvest in mice prophylactically treated with S2 stem-helix bnAbs or DEN3 control mAb. d., g., j. Day 2 post-infection pulmonary function (shown as Penh score) was measured by whole body plethysmography in mice prophylactically treated with S2 stem-helix bnAbs or DEN3 control mAb. Statistical comparisons between groups were performed using a Kruskal-Wallis non-parametric test and significance was calculated with Dunnett’s multiple comparisons test between each experimental group and the DEN3 control Ab group. (p <0.05, **p <0.01, ***p <0.001; ****p < 0.0001; ns- p >0.05).

Article Snippet: Using SARS-CoV-2 and MERS-CoV S-proteins as baits, we sorted antigen-specific single B cells to isolate 40 stem-helix mAbs from 10 COVID-19 convalescent donors who had been recently vaccinated with the Pfizer/BioNTech BNT162b2 (n = 4: CC9, CC92, CC95 and CC99), Johnson & Johnson Ad26.CoV2.S (n = 1: CC67), or Moderna mRNA-1273 (n = 5: CC24, CC25, CC26, CC67, CC84) vaccines ( , , ) ( , , ).

Techniques: Control, Virus, Infection